These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 11809847

  • 1. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase.
    Sienaert R, Naesens L, Brancale A, De Clercq E, McGuigan C, Balzarini J.
    Mol Pharmacol; 2002 Feb; 61(2):249-54. PubMed ID: 11809847
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
    Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, McGuigan C.
    Mol Pharmacol; 2002 May; 61(5):1140-5. PubMed ID: 11961132
    [Abstract] [Full Text] [Related]

  • 5. Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase.
    Sienaert R, Andrei G, Snoeck R, De Clercq E, McGuigan C, Balzarini J.
    Biochem Biophys Res Commun; 2004 Mar 19; 315(4):877-83. PubMed ID: 14985094
    [Abstract] [Full Text] [Related]

  • 6. Bicyclic nucleoside inhibitors of varicella-zoster virus modified on the sugar moiety: 3' and 5' derivatives.
    Luoni GM, McGuigan C, Andrei G, Snoeck R, De Clercq E, Balzarini J.
    Antivir Chem Chemother; 2004 Nov 19; 15(6):333-41. PubMed ID: 15646647
    [Abstract] [Full Text] [Related]

  • 7. The development of BVDU: An odyssey.
    De Clercq E.
    Antivir Chem Chemother; 2023 Nov 19; 31():20402066231152971. PubMed ID: 36710501
    [Abstract] [Full Text] [Related]

  • 8. Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
    Degrève B, Esnouf R, De Clercq E, Balzarini J.
    Mol Pharmacol; 2001 Feb 19; 59(2):285-93. PubMed ID: 11160865
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
    Andrei G, Sienaert R, McGuigan C, De Clercq E, Balzarini J, Snoeck R.
    Antimicrob Agents Chemother; 2005 Mar 19; 49(3):1081-6. PubMed ID: 15728906
    [Abstract] [Full Text] [Related]

  • 11. 2'-Fluorosugar analogues of the highly potent anti-varicella-zoster virus bicyclic nucleoside analogue (BCNA) Cf 1743.
    McGuigan C, Derudas M, Quintiliani M, Andrei G, Snoeck R, Henson G, Balzarini J.
    Bioorg Med Chem Lett; 2009 Nov 15; 19(22):6264-7. PubMed ID: 19833513
    [Abstract] [Full Text] [Related]

  • 12. Metabolic and pharmacological characteristics of the bicyclic nucleoside analogues (BCNAs) as highly selective inhibitors of varicella-zoster virus (VZV).
    Sienaert R, Naesens L, Brancale A, Carangio A, Andrei G, Snoeck R, Van Kuilenburg A, De Clercq E, McGuigan C, Balzarini J.
    Nucleosides Nucleotides Nucleic Acids; 2003 Nov 15; 22(5-8):995-7. PubMed ID: 14565329
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine.
    Degrève B, Esnouf R, De Clercq E, Balzarini J.
    Mol Pharmacol; 2000 Dec 15; 58(6):1326-32. PubMed ID: 11093770
    [Abstract] [Full Text] [Related]

  • 15. Susceptibility of protein kinase (ORF47)-deficient varicella-zoster virus strains to anti-herpesvirus nucleosides.
    Suzutani T, Ogasawara M, Shibaki T, Azuma M.
    Antiviral Res; 2000 Jan 15; 45(1):79-82. PubMed ID: 10774592
    [Abstract] [Full Text] [Related]

  • 16. Testing the sensitivities of noncognate inhibitors to varicella zoster virus thymidine kinase: implications for postherpetic neuralgia therapy with existing agents.
    Yang L, Mo X, Yang H, Dai H, Tan F.
    J Mol Model; 2014 Jul 15; 20(7):2321. PubMed ID: 24961898
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antiviral activity of oxetanocins against varicella-zoster virus.
    Sakuma T, Saijo M, Suzutani T, Yoshida I, Saito S, Kitagawa M, Hasegawa S, Azuma M.
    Antimicrob Agents Chemother; 1991 Jul 15; 35(7):1512-4. PubMed ID: 1656865
    [Abstract] [Full Text] [Related]

  • 20. Structure-activity relationship of the affinity of 5-substituted uracil nucleoside analogues for varicella-zoster virus thymidine kinase and their activity against varicella-zoster virus.
    Ashida N, Watanabe Y, Miura S, Kano F, Sakata S, Yamaguchi T, Suzutani T, Machida H.
    Antiviral Res; 1997 Aug 15; 35(3):167-75. PubMed ID: 9298756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.